Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SBB in connection with the sale of properties to a company co-owned with Kåpan
Mandate

Vinge has advised SBB in connection with the sale of properties to a company co-owned with Kåpan

November 19, 2021 Capital Markets and Public M&A

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (”SBB”) in connection with the sale of properties for SEK 10 billion to a company co-owned by Kåpan with a focus on government infrastructure.

In the transaction, SBB sold properties for an agreed property value of SEK 10 billion within government infrastructure to a jointly owned company with Kåpan Occupational Pension Association (“Kåpan”). The properties have an annual rental income of approximately SEK 584 million and an operating net of SEK 435 million. The leasable area is approximately 500,000 sqm. In parallel with the transaction, SBB acquires 23 percent of the shares in the community service property company Stenvalvet AB (publ) (“Stenvalvet”) from Kåpan and thus, together with Kåpan, becomes a major owner in Stenvalvet.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson and Anna Svensson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025